Another study compared 296 patients with spondyloarthropathy (of which 198 had AS) receiving anti-TNF-α agents (IFX/ADA/ETN) with 112 patients taking disease modifying antirheumatic drugs (DMARDs), to evaluate the paradoxical IBD development [2]. This evidence concerns the gene TNF and inflammatory bowel disease.